169 related articles for article (PubMed ID: 1849465)
1. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Waud WR; Harrison SD; Gilbert KS; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1991; 27(6):456-63. PubMed ID: 1849465
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
Harrison SD; O'Dwyer PJ; Trader MW
Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
[TBL] [Abstract][Full Text] [Related]
3. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo.
Harrison SD; Brockman RW; Trader MW; Laster WR; Griswold DP
Invest New Drugs; 1987 Dec; 5(4):345-51. PubMed ID: 3436739
[TBL] [Abstract][Full Text] [Related]
4. Cross-resistance of drug-resistant murine P388 leukemias to taxol in vivo.
Waud WR; Gilbert KS; Harrison SD; Griswold DP
Cancer Chemother Pharmacol; 1992; 31(3):255-7. PubMed ID: 1361163
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
[TBL] [Abstract][Full Text] [Related]
8. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
Baguley BC; Holdaway KM; Fray LM
J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584
[TBL] [Abstract][Full Text] [Related]
9. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
Kruczynski A; Barret JM; Van Hille B; Chansard N; Astruc J; Menon Y; Duchier C; Créancier L; Hill BT
Clin Cancer Res; 2004 May; 10(9):3156-68. PubMed ID: 15131057
[TBL] [Abstract][Full Text] [Related]
10. Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias.
Waud WR; Gilbert KS; Secrist JA
Cancer Chemother Pharmacol; 2011 Aug; 68(2):399-403. PubMed ID: 21069340
[TBL] [Abstract][Full Text] [Related]
11. In vivo response of mitoxantrone and doxorubicin with dipyrone in parental and doxorubicin-resistant P388 leukemia.
Kamath NS; Chitnis MP
Oncology; 1990; 47(2):166-9. PubMed ID: 2314829
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211
[TBL] [Abstract][Full Text] [Related]
13. Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II.
Deffie AM; McPherson JP; Gupta RS; Hedley DW; Goldenberg GJ
Biochem Cell Biol; 1992 May; 70(5):354-64. PubMed ID: 1353968
[TBL] [Abstract][Full Text] [Related]
14. Antitumor drug cross-resistance in vivo in a murine P388 leukemia resistant to ethyl 5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7 - ylcarbamate 2-hydroxyethanesulfonate hydrate (NSC 370,147) 370147.
Waud WR; Harrison SD; Temple CG; Griswold DP
Cancer Chemother Pharmacol; 1992; 29(3):190-4. PubMed ID: 1733551
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of combination of antitumor agent with AHC-52 against multidrug-resistant cells in the intravenously inoculated P388 leukemia model.
Shinoda H; Ebisu H; Mitsuhashi J; Inaba M; Tsuruo T
Cancer Chemother Pharmacol; 1992; 30(5):335-40. PubMed ID: 1505070
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
Zwelling LA; Mayes J; Hinds M; Chan D; Altschuler E; Carroll B; Parker E; Deisseroth K; Radcliffe A; Seligman M
Biochemistry; 1991 Apr; 30(16):4048-55. PubMed ID: 1850298
[TBL] [Abstract][Full Text] [Related]
17. [Topoisomerase II mediated DNA strand cleavage and antitumor activities against murine leukemia P388 of novel acridines].
Kimura M
Yakugaku Zasshi; 1994 May; 114(5):304-7. PubMed ID: 8014839
[TBL] [Abstract][Full Text] [Related]
18. In vivo characterization of P388 leukemia resistant to mitomycin C.
Rose WC; Huftalen JB; Bradner WT; Schurig JE
In Vivo; 1987; 1(1):47-52. PubMed ID: 2979764
[TBL] [Abstract][Full Text] [Related]
19. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
[TBL] [Abstract][Full Text] [Related]
20. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
Li LH; DeKoning TF; Wallace TL
Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
